Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163299 | 0.90 | MET (0.74) | METMAPK1PLA2G7MGLLABHD6 | |
| SCHEMBL1163126 | 0.86 | MET (0.65) | METMAPK1PLA2G7MGLLABHD6 | |
| SCHEMBL1163259 | 0.83 | MET (0.59) | METMAPK1PLA2G7MGLLABHD6 | |
| SCHEMBL9101308 | 0.81 | MET (1.00) | MET | |
| SCHEMBL10162886 | 0.81 | MET (1.00) | MET | |
| SCHEMBL6526605 | 0.81 | MET (1.00) | MET | |
| SCHEMBL6526607 | 0.81 | MET (1.00) | MET | |
| SCHEMBL9101312 | 0.81 | MET (1.00) | MET | |
| SCHEMBL1660036 | 0.78 | MET (0.54) | MET | |
| SCHEMBL1163354 | 0.73 | MET (0.49) | METPLA2G7MGLLABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | MET, HGF, RET | MET 1/4885MAPK1 157/4885PLA2G7 4007/4885 |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | MET 1/4885MAPK1 187/4885PLA2G7 3857/4885 |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | MET 1/4885MAPK1 187/4885PLA2G7 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.